<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04578678</url>
  </required_header>
  <id_info>
    <org_study_id>2019-00475</org_study_id>
    <nct_id>NCT04578678</nct_id>
  </id_info>
  <brief_title>Can Subthalamic Stimulation Using Directional Electrodes Improve Postoperative Management in Parkinson's Disease</brief_title>
  <acronym>Steeropt</acronym>
  <official_title>Can Subthalamic Stimulation Using Directional Electrodes Improve Postoperative Management in Parkinson's Disease: A Post-market Study - Steeropt</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Inselspital, Berne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Boston Scientific Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital Inselspital, Berne</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study is to determine if subthalamic nucleus (STN) deep brain&#xD;
      stimulation (DBS) using the Vercise directional leads improves neuropsychiatric state and&#xD;
      neuropsychiatric fluctuations 12 months after surgery in a large consecutive series of&#xD;
      STN-DBS Parkinson's disease (PD) patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This project of further use of health-related data with consent by the participants is a&#xD;
      prospective, international project to evaluate the improvement of neuropsychiatric symptoms&#xD;
      and the quality of life 12 months after surgery in a large consecutive series of STN-DBS PD&#xD;
      patients using novel implantable Neurostimulator Systems (Boston Scientific). The project&#xD;
      will investigate if a fine tuning of the STN-DBS settings could alleviate neuropsychiatric&#xD;
      fluctuations, apathy as well as DBS-induced dysarthria and global motor state. The tuning is&#xD;
      performed in agreement with the instruction for use of all devices used. Further objectives&#xD;
      are validation of new tools that are presently entering clinical routine in optimizing&#xD;
      postoperative management like individual current sources, steering, imaging of volume of&#xD;
      tissue activated, and beta-oscillations.&#xD;
&#xD;
      The data originates from patients suffering from levodopa-responsive PD which are not&#xD;
      adequately controlled by dopaminergic medication and therefore receive STN-DBS as a routine&#xD;
      standard of care with routinely collected data.&#xD;
&#xD;
      In total 110 patients who are candidates for STN-DBS will be enrolled in four participating&#xD;
      sites in Switzerland and the EU.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 9, 2019</start_date>
  <completion_date type="Anticipated">May 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of non-motor fluctuations</measure>
    <time_frame>Follow-up ≤ 5 Weeks</time_frame>
    <description>Evaluation of the Neuropsychiatric Fluctuations Scale (NFS) in different states (ON/OFF) to evaluate if non-motor fluctuations are present. The bigger the difference between the two subscores ('ON psychological state' and 'OFF psychological sate') in the different states are, the more non-motor fluctuations are present.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of motor improvement</measure>
    <time_frame>Follow-up ≤ 5 Weeks</time_frame>
    <description>Motor improvement following STN-DBS using the Vercise directional leads will be assessed by comparing MDS-UPDRS III score (International Parkinson and Movement Disorder Society) during the study in different states (ON/OFF). The minimum and maximum values are: 0-132, where a higher score means a worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of STN-DBS induced dysarthria</measure>
    <time_frame>Follow-up ≤ 5 Weeks</time_frame>
    <description>Dysarthria will be measured during the study by Voice Handicap Index 30 (VHI) scale. The minimum and maximum values are: 0-120, where a higher score means a worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of postoperative apathy</measure>
    <time_frame>Follow-up ≤ 5 Weeks</time_frame>
    <description>Apathy will be measured during the study by Dimensional Apathy Scale (DAS). The minimum and maximum values are: 0-72, where a higher score means a worse outcome.</description>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">110</enrollment>
  <condition>Parkinson's Disease</condition>
  <condition>Deep Brain Stimulation</condition>
  <arm_group>
    <arm_group_label>Apathy Group</arm_group_label>
    <description>Patients diagnosed with apathy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dysarthria Group</arm_group_label>
    <description>Patients diagnosed with dysarthria</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No Apathy and Dysarthria Group</arm_group_label>
    <description>Patients diagnosed with neither apathy nor dysarthria</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Apathy and Dysarthria Group</arm_group_label>
    <description>Patients diagnosed with apathy as well as dysarthria</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Steering</intervention_name>
    <description>Fine tuning of the STN-DBS settings</description>
    <arm_group_label>Apathy Group</arm_group_label>
    <arm_group_label>Apathy and Dysarthria Group</arm_group_label>
    <arm_group_label>Dysarthria Group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The project population consists of PD patients suffering from levodopa-responsive PD which&#xD;
        are not adequately controlled by dopaminergic medication and therefore receive STN-DBS as a&#xD;
        routine standard of care.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        For all subjects:&#xD;
&#xD;
          -  Informed consent as documented by signature&#xD;
&#xD;
          -  Diagnosis of PD based on the MDS clinical diagnostic criteria for Parkinson's disease&#xD;
&#xD;
          -  Fulfilling criteria for STN-DBS:&#xD;
&#xD;
          -  The presence of disabling motor complications of dopaminergic treatment&#xD;
&#xD;
          -  The absence of surgical contraindications&#xD;
&#xD;
          -  Planned bilateral STN-DBS using steering electrodes in the next 3 months (routine&#xD;
             standard of care)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Presence of dementia as indicated by a score ≤ 25 on the MOntreal Cognitive Assessment&#xD;
             (MOCA)&#xD;
&#xD;
          -  Depression with acute suicidal ideation&#xD;
&#xD;
          -  Presence of major ongoing psychiatric illness&#xD;
&#xD;
          -  Non-compensated systemic disease (i.e., diabetes, hypertension)&#xD;
&#xD;
          -  Inability to follow the procedures of the study, e.g. due to language problems,&#xD;
             psychological disorders, dementia, etc. of the participant&#xD;
&#xD;
          -  Participation in interventional trial within the 30 days preceding and during the&#xD;
             present study&#xD;
&#xD;
          -  Previous enrolment into the current study&#xD;
&#xD;
          -  Enrolment of any study site personnel, their family members, employees or other&#xD;
             dependent persons&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ines Debove, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Insel Gruppe AG University Hospital Bern</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ines Debove, MD</last_name>
    <phone>+41 31 632 79 24</phone>
    <email>ines.debove@insel.ch</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospices Civils de Lyon (Centre Hospitalier Universitaire de Lyon)</name>
      <address>
        <city>Lyon</city>
        <zip>69002</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Pitié-Salpêtrière</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Würzburg</name>
      <address>
        <city>Würzburg</city>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Insel Gruppe AG University Hospital Bern</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ines Debove, MD</last_name>
      <email>ines.debove@insel.ch</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>September 8, 2020</study_first_submitted>
  <study_first_submitted_qc>September 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 8, 2020</study_first_posted>
  <last_update_submitted>August 2, 2021</last_update_submitted>
  <last_update_submitted_qc>August 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Apathy</keyword>
  <keyword>Dysarthria</keyword>
  <keyword>Neuropsychiatric Symptoms</keyword>
  <keyword>Steering</keyword>
  <keyword>Non-motor Symptoms</keyword>
  <keyword>Motor State</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

